Complex disease-, gene-, and drug-drug interactions: Impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics

Clinical Cancer Research

Volumn 20, Issue 15, 2014, Pages 3931-3944

  Li, Jing ^a   Kim, Seongho ^a   Sha, Xianyi ^a,b   Wiegand, Richard ^a   Wu, Jianmei ^a   Lorusso, Patricia ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYTOCHROME P450 2D6; DRUG METABOLITE; IRINOTECAN; ORGANIC CATION TRANSPORTER 2; VELIPARIB; BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ORGANIC CATION TRANSPORTER; SLC22A2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RELEASE; ENZYME ACTIVITY; ENZYME KINETICS; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIVER METABOLISM; LIVER MICROSOME; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN METABOLISM; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; URINARY EXCRETION; BIOLOGICAL MODEL; CHEMICALLY INDUCED; DRUG INTERACTION; GENETIC VARIATION; GENETICS; KIDNEY FAILURE; METABOLISM; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); TISSUE DISTRIBUTION;

BENZIMIDAZOLES; CLINICAL TRIALS, PHASE I AS TOPIC; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ENZYME INHIBITORS; GENETIC VARIATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; ORGANIC CATION TRANSPORT PROTEINS; PHENOTYPE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RENAL INSUFFICIENCY; TISSUE DISTRIBUTION;

EID: 84905495529     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0791     Document Type: Article

References (29)

1. Jagtap P, Szabo C. Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40.
2. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced expression of poly (ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 1991;37:223-7.
3. Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F, et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:338-44.
4. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:2705-11.
5. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011;71:5626-34.
6. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012;18:1726-34.
7. Salem AH, Giranda VL, Mostafa NM. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic Malignancies. Clin Pharmacokinet 2014;53:479-88.
8. Kikuchi R, Lao Y, Bow DA, Chiou WJ, Andracki ME, Carr RA, et al. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). J Pharm Sci 2013;102:4426-32.
9. Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, et al. Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther 2013;94:52-63.
10. Li X, Delzer J, Voorman R, De Morais SM, Lao Y. Disposition and drugdrug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly (ADP-ribose) polymerase. Drug Metab Dispos 2011;39:1161-9.
11. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, et al. Discovery of the Poly (ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2- yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 2009;52:514-23.
12. Palma JP, Rodriguez LE, Bontcheva-Diaz VD, Bouska JJ, Bukofzer G, Colon-Lopez M, et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008;28:2625-35.
13. Hsu V, De L T V M, Zhao P, Zhang L, Zheng JH, Nordmark A, et al. Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet 2014;53:283-93.
14. Grillo JA, Zhao P, Bullock J, Booth BP, Lu M, Robie-Suh K, et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos 2012;33:99-110.
15. Houston JB, Galetin A. Methods for predicting in vivo pharmacokinetics usingdata frominvitroassays. CurrDrugMetab 2008;9:940-51.
16. Wiegand R, Wu J, Sha X, Lo Russo P, Li J. Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:333-9.
17. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999;58:51-64.
18. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997;37:486-95.
19. Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008;35:185-202.
20. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clinical Pharmacol Ther 2002;71:115-21.
21. Breyer MD, Qi Z. Better nephrology for mice and man. Kidney Int 2010;77:487-9.
22. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genom 2009;19:497-504.
23. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002;12:395-405.
24. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008;14:3875-80.
25. Nelson JA, Santos G, Herbert BH. Mechanisms for the renal secretion of cisplatin. Cancer Treat Rep 1984;68:849-53.
26. Williams PD, Hottendorf GH. Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex. Cancer Treat Rep 1985;69:875-80.
27. Miura K, Goldstein RS, Pasino DA, Hook JB. Cisplatin nephrotoxicity: role of filtration and tubular transport of cisplatin in isolated perfused kidneys. Toxicology 1987;44:147-58.
28. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatininduced nephrotoxicity. Clin Pharmacol Ther 2009;86:396-402.
29. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-43. advertisement in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.